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ABSTRACT Campylobacter spp. are foodborne and waterborne pathogens. While
rather accurate estimates for these pathogens are available in industrialized coun-
tries, a lack of diagnostic capacity in developing countries limits accurate assess-
ments of prevalence in many regions. Proﬁciency in the identiﬁcation and suscepti-
bility testing of these organisms is critical for surveillance and control efforts. The
aim of the study was to assess performance for identiﬁcation and susceptibility test-
ing of thermotolerant Campylobacter spp. among laboratories participating in the
World Health Organization (WHO) Global Foodborne Infections Network (GFN) Exter-
nal Quality Assurance System (EQAS) over a 9-year period. Participants (primarily
national-level laboratories) were encouraged to self-evaluate their performance as
part of continuous quality improvement. The ability to correctly identify Campylo-
bacter spp. varied by year and ranged from 61.9% (2008) to 90.7% (2012), and the
ability to correctly perform antimicrobial susceptibility testing (AST) for Campylobac-
ter spp. appeared to steadily increase from 91.4% to 93.6% in the test period (2009
to 2012). The poorest performance (60.0% correct identiﬁcation and 86.8% correct
AST results) was observed in African laboratories. Overall, approximately 10% of lab-
oratories reported either an incorrect identiﬁcation or antibiogram. As most partici-
pants were supranational reference laboratories, these data raise signiﬁcant concerns
regarding capacity and proﬁciency at the local clinical level. Addressing these diag-
nostic challenges is critical for both patient-level management and broader surveil-
lance and control efforts.
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Campylobacteriosis in humans typically presents as acute diarrhea with fever. How-ever, more signiﬁcant sequelae, such as Guillain-Barré syndrome (GBS), reactive
arthritis (ReA), and irritable bowel syndrome (IBS), have been reported following
Campylobacter gastroenteritis (1).
Most human cases are caused by thermotolerant Campylobacter spp., which are
zoonotic bacteria found in animals, such as poultry, cattle, and pigs, as well as
contaminants of various foodstuffs and water (2, 3).
Campylobacter jejuni and Campylobacter coli are the most commonly implicated
species, and campylobacteriosis is the most frequently reported bacterial foodborne
illness in most developed countries. However, data from developing countries are often
limited by a lack of diagnostic capacity (1, 2, 4).
Antimicrobials are typically not suggested for treatment of mild/moderate enteritis
in otherwise healthy individuals. However, antimicrobial therapy may be warranted for
severe or bloody diarrhea. Antimicrobials are also used in the management of extraint-
estinal (invasive) infections. Macrolides (e.g., erythromycin and azithromycin) are com-
monly used for empirical treatment of campylobacteriosis, and ﬂuoroquinolones (e.g.,
ciproﬂoxacin) may be a second-line therapy for adults. Accurate antimicrobial suscep-
tibility testing is critical for developing empirical therapy guidelines and monitoring
emerging resistance. Increasing antimicrobial resistance (AMR), especially multidrug
resistance to ﬂuoroquinolones and azithromycin, signiﬁcantly limits treatment options
for severe/invasive disease. Access to last-line drugs, such as carbapenems, is often
beyond the reach of many people in the developing world (5).
Since 2000, the World Health Organization (WHO) Global Foodborne Infections
Network (GFN) (formerly WHO Global Salm-Surv [WHO GSS]) has functioned as an
international platform to enhance the capacity of countries to detect, control, and
prevent foodborne and other enteric infections. Part of this capacity-building work has
focused on identiﬁcation and susceptibility testing of Campylobacter spp. Since 2000,
the WHO GFN has offered members the opportunity to participate at no cost in an
annual External Quality Assurance System (EQAS). Although the primary focus of the
EQAS is serotyping and antimicrobial susceptibility testing (AST) of Salmonella spp.,
identiﬁcation and AST of Campylobacter spp. are included as a separate module.
Laboratories may choose to participate in all or some components. Approximately 200
laboratories participate in one or more components of the EQAS. Of these laboratories,
approximately 50% will participate in the Campylobacter module. The WHO GFN
program focuses activities mainly at reference-level facilities (supranational, national, or
subnational). While some of these facilities may perform clinical testing, clinical diag-
nostic laboratories typically do not participate in EQAS (6, 7). Participants report results
electronically and receive their results immediately. Participants are encouraged to
utilize their results as part of continuous quality improvement.
The aim of this paper is to summarize and describe temporal and geographic trends
in the performance of the Campylobacter component of the EQAS (identiﬁcation and
AST) observed between 2003 and 2012.
MATERIALS AND METHODS
The Campylobacter identiﬁcation component has included C. jejuni and C. coli since 2003 and
Campylobacter lari from 2003 to 2008. AST of C. jejuni and C. coli has been included since 2009. Due to
the limited availability of epidemiological cutoff values (ECOFFs) for other Campylobacter spp., the AST
component includes only C. jejuni and C. coli. Since 2003, the Technical University of Denmark, National
Food Institute (DTU Food), in collaboration with members of the WHO GFN steering committee, has
organized this proﬁciency test annually (except 2005). DTU Food coordinated the selection of test strains
and veriﬁed the identiﬁcation and AST of test strains. The results obtained by DTU Food were recon-
ﬁrmed in a blind manner by a referee laboratory (U.S. Centers for Disease Control and Prevention [CDC]).
Further details on the preparatory work and the EQAS setup are described in the annual EQAS reports
available online (http://www.who.int/gfn/activities/eqas/en/).
While the target audience for the EQAS is national public health, food, and veterinary reference
laboratories, in special instances (particularly in countries without a designated referral laboratory), the
organizers occasionally permit a select number of clinical and/or research laboratories to participate in
the EQAS. EQAS participants have the option to participate in all or some of the components. Participants
in the WHO GFN proﬁciency test for identiﬁcation and/or AST of Campylobacter spp. receive two vials,
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each containing a lyophilized Campylobacter isolate (challenge strains). In addition, all laboratories
participating in the Campylobacter AST component were provided an isolate of C. jejuni ATCC 33560
upon request. Protocols available online (http://www.antimicrobialresistance.dk/233-169-215-eqas.htm)
describe how to revive and test the isolates and refer to a manual on subculturing and maintaining
quality control (QC) strains.
For the identiﬁcation component, the protocol speciﬁed that the laboratory’s routine methods
should be applied. Laboratories were free to utilize conventional phenotypic identiﬁcation, molecular
identiﬁcation, or a combination of methods for identiﬁcation. Laboratories that participated in only the
AST component (i.e., did not perform identiﬁcation) were provided upon request the identiﬁcation of the
coded Campylobacter strains.
While multiple methods were used for identiﬁcation, during this period, validated methods for
susceptibility testing of Campylobacter spp. by disk diffusion or Etest were not internationally available.
As such, only broth or agar dilution methods (measuring the MIC) were accepted for the AST component.
Epidemiological cutoff values (ECOFFs) for the interpretation of disk diffusion zones for ciproﬂoxacin,
erythromycin, and tetracycline against C. coli, as well as against ciproﬂoxacin, erythromycin, tetracycline,
and gentamicin for C. jejuni are now incorporated into the EUCAST guidelines. Participants could test and
submit results for chloramphenicol (CHL), ciproﬂoxacin (CIP), erythromycin (ERY), gentamicin (GEN),
nalidixic acid (NAL), streptomycin (STR), and tetracycline (TET). The protocol listed the interpretative
criteria applied for this EQAS, i.e., ECOFFs according to EUCAST (http://www.eucast.org), which allowed
two categories of characterization (resistant [R; non-wild type], or susceptible [S; wild type]) for the C.
jejuni and C. coli test strains.
The WHO GFN EQAS was set up as a self-evaluating system in which participants, directly upon
submission of results, received a report comparing their obtained results with quality-assured and
veriﬁed expected results and itemizing the laboratory’s eventual deviations. Deviations for the identiﬁ-
cation component were reported as incorrect results, and no attempt was made to quantify their
severity. For the AST component, the acceptance limit was set at 5% deviations, i.e., one deviation would
categorize the laboratory’s results as unacceptable. The analysis was based on assigning all results the
same level of inﬂuence, i.e., disregarding the impact of the variation in the selection of test strains from
year to year (the susceptibility testing of some strains could be more difﬁcult than others) and the various
participation levels (some years, more laboratories participated than in other years).
For each of the world regions, the annual proportions of correctly identiﬁed species were analyzed
for (i) signiﬁcant variation between the years 2003 and 2012 using the function Fisher.test in R and (ii)
a time trend from 2003 to 2012 by performing a chi-square test for trend in proportions using the
function prop.trend.test from the R package stats. Next, for each region, the data were aggregated to the
overall proportion of correctly identiﬁed Campylobacter species over the whole period from 2003 to
2012. These data were used to test if the proportions of correctly identiﬁed species were different
between the regions using the prop.test function in the R package stats.
To assess potential differences between regions in AST performance, the proportions of correct AST
results for each antibiotic (CHL, CIP, ERY, GEN, NAL, STR, and TET) were analyzed for signiﬁcant differences
between regions using the prop.test function in the stat R package stats.
All presented 95% conﬁdence intervals for the proportions were obtained using the function binconf
in the R package Hmisc.
RESULTS
In total, laboratories from 96 countries (Fig. 1) participated in the Campylobacter sp.
identiﬁcation and/or AST component of the EQAS in one or more iterations from 2003
to 2012; the list included national and other reference laboratories from the veterinary,
food, and public health sectors.
For the identiﬁcation component of the EQAS, the number of countries participating
each year were 53 (2003), 62 (2004), 59 (2006), 59 (2007), 63 (2008), 54 (2009), 62 (2010),
57 (2011), and 69 (2012). In some cases, multiple laboratories from a country partici-
pated in the EQAS (e.g., Ministry of Health [MoH] and Ministry of Agriculture [MoA]
laboratories). The cumulative numbers of laboratories participating in the Campylobac-
ter module were 97, 111, 100, 104, 112, 92, 100, 82, and 112 in the years 2003 to 2012,
respectively.
For the AST of Campylobacter spp., the numbers of participating countries from each
region in the years 2009, 2010, 2011, and 2012, respectively, were 2, 2, 7, and 4 for
Africa; 1, 1, 1, and 3 for Asia and the Middle East; 0, 0, 0, and 1 for the Caribbean; 7, 9,
7, and 11 for Europe; 4, 7, 6, and 6 for Latin America; 1, 2, 2, and 2 for North America;
0, 0, 1, and 0 for Oceania; 0, 1, 1, and 0 for Russia; and 4, 5, 4, and 6 for Southeast Asia.
The cumulative numbers of laboratories participating from each country were 25, 37,
38, and 47 for the years 2009 to 2012, respectively. In all, 18 laboratories participated
twice, 14 laboratories participated three times, and 11 laboratories participated in all
four Campylobacter AST iterations from 2009 to 2012.
The overall ability to correctly identify Campylobacter spp. ﬂuctuated over the years
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2003 to 2012 (Fig. 2), and when focusing on C. coli and C. jejuni bacteria between the
regions, a signiﬁcant difference could be identiﬁed in Europe and Latin America in the
proportion of correctly identiﬁed Campylobacter species between years (data not
shown). No time-related trend was identiﬁed in Europe or Latin America, and other
factors (such as new laboratories joining or previous participants leaving the program)
likely contributed to this variation. A signiﬁcant variation between the years was not
found in any other regions.
There was a signiﬁcant difference between the regions as to the proportion of
correctly identiﬁed Campylobacter species, with Oceania and North America exhibiting
the highest and Africa and the Caribbean exhibiting the lowest proportions of correctly
identiﬁed Campylobacter species (Fig. 3). It is important to consider that in some
regions (e.g., Oceania), participation was limited (n  1) and may fail to reﬂect true
regional capacity.
In the iterations from 2003 to 2012, identiﬁcations were correctly performed
between 59.3% (2011, C. coli, n  81) and 96.4% (2012, C. jejuni, n  112), with an
average over the years of 79.3% (based on the result of two isolates per year, i.e.,
18 isolates in total of C. jejuni, C. coli, and C. lari; total number of observations, n 
1,736). Comparing the species, it appears that participants were more able to
correctly identify C. jejuni (90.4% correct) than C. coli and C. lari (74.1% and 68.8%
correct identiﬁcations, respectively). This result was not unexpected, as, typically, C.
jejuni is readily identiﬁed by hippurate hydrolysis, whereas other species require
additional more complex tests.
Subsequent to the validation of the submitted data, 1,565 AST results were included
FIG 1 Map indicating the participating countries colored with respect to the region to which they belong (Africa, Asia/Middle East, Caribbean, Europe, Latin
America, North America, Oceania, Russia, or Southeast Asia). Performance with regard to the species identiﬁcation and antimicrobial susceptibility testing is
indicated as average % of correct results. The 96 participating countries included the following, by region: in Africa, Algeria, Botswana, Cameroon, Central
African Republic, Republic of the Congo, Egypt, Ethiopia, Gambia, Gabon, Ivory Coast, Kenya, Madagascar, Malawi, Mauritius, Morocco, Senegal, South Africa,
Sudan, and Tunisia; in Asia and the Middle East, China, Islamic Republic of Iran, Israel, Kuwait, Oman, and Saudi Arabia; in the Caribbean, Barbados, Grenada,
Jamaica, and Trinidad and Tobago; in Europe, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Germany, Greece,
Hungary, Iceland, Italy, Latvia, Lithuania, Luxembourg, Macedonia, Malta, Republic of Moldova, The Netherlands, Norway, Poland, Romania, Serbia, Slovakia,
Slovenia, Spain, and Turkey; in Latin America, Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Ecuador, El Salvador, Guatemala, Mexico, Panama,
Paraguay, Peru, Suriname, Uruguay, and Venezuela; in North America, Canada, and the United States; in Oceania, Australia, New Caledonia, and New Zealand;
in the Russian region, Belarus, Georgia, Russian Federation, and Ukraine; and in Southeast Asia, Brunei Darussalam, Cambodia, India, Japan, Republic of Korea,
Lao People’s Democratic Republic, Malaysia, the Philippines, Singapore, Sri Lanka, Taiwan, Thailand, and Vietnam.
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for analysis for the eight Campylobacter isolates in the four iterations from 2009 to 2012.
Of these results, 7.3% deviated from the expected. For all antimicrobials included in the
antimicrobial susceptibility performance test, there was a signiﬁcant difference be-
tween the performances of the regions, where Europe and North America exhibited the
highest correspondence with the expected results and Southeast Asia the lowest (Fig.
4). Additionally, results from Oceania presented a high performance percentage (100%),
FIG 2 Species identiﬁcation of Campylobacter. Summary of the performance per year of results covering all nine
participating regions (Africa, Asia/Middle East, Caribbean, Europe, Latin America, North America, Oceania, Russia,
and Southeast Asia).
FIG 3 Species identiﬁcation of Campylobacter coli and C. jejuni. Summary of the performance per region of results over the
years 2003 to 2012 (excluding 2005).
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and results from the Caribbean region presented a low percentage (75%); however,
these results should be interpreted with care, as they represent results from a limited
number of laboratories per region (n  1).
Deviations from the expected results appeared to be particularly related to strep-
tomycin, with a deviation level at 11.5%; however, fairly high deviation levels were also
seen for erythromycin, tetracycline, and ciproﬂoxacin, (8.5%, 8.1%, and 6.4%, respec-
tively). In particular, one bacterial strain, WHO 2009 C-9.2 (resistant [non-wild type] to
CIP, NAL, and TET), caused a high level of deviation, with 11.3% of the submitted results
deviating from the expected. A low deviation level (4.2%) was obtained for chloram-
phenicol, to which all the test strains were susceptible (wild type). When the obtained
results from all laboratories that participated in the AST component in one or more of
the four iterations were compared, a slight increase in performance was observed
across the years from 2009 to 2012 (Fig. 5). Disregarding results from the Caribbean and
Oceania regions due to the limited number of submitted results, the summary of the
4 years of results per region provided an indication of a generally low performance of
the participants in the Southeast Asian region and the African region, with deviation
levels at 17.0% and 13.2%, respectively. In 2012, however, all regions except Southeast
Asia (deviation level, 14.2%) exhibited deviation levels lower than 10% (the Russian
region did not participate in the 2012 iteration).
In the four iterations, 51 (75%) laboratories uploaded one or more values for the QC
reference strain C. jejuni ATCC 33560, suggesting that 25% of the labs did not test the
QC strain for reference. Of the submitted values for the QC reference strain, an average
of 17.2% were out of the QC range when evaluated against one of the validated
methods described by the CLSI (e.g., VET01-A4) (8). An analysis of regional differences
in this context revealed Africa to be the region with the highest level of laboratories
submitting AST results for the Campylobacter test strains without submitting results for
the C. jejuni ATCC 33560 reference strain.
FIG 4 Antimicrobial susceptibility testing of Campylobacter spp. showing the performance per year and region.
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The proﬁciency test results are intended to be utilized for continuous quality
improvement. However, some participating laboratories did not demonstrate improve-
ment in identiﬁcation or AST over time. Information about corrective actions imple-
mented in the individual laboratories based on the deviations in their evaluation report
could have added to the analysis but unfortunately was not available. This proﬁciency
test shows a worrisome tendency, where even national reference laboratories in
regions normally anticipated to perform ﬂawlessly have approximately 10% incorrect
results in both tests. Given the complex microbiology of Campylobacteraceae and the
fastidious nature of these organisms, when these results are extrapolated to ﬁrst-line
facilities, such as clinical laboratories, the ability to correctly identify and perform
antimicrobial susceptibility tests on Campylobacter spp. is likely substantially higher
than the 10% error observed among participating laboratories. In addition, results for
Campylobacter spp. were received only from50% of the total number of participating
laboratories in the WHO GFN EQAS. This suggests that nearly 50% of participants lack
a basic capacity for testing Campylobacter spp. These ﬁndings are worrying in light of
the importance of the Campylobacter spp. as a foodborne pathogen. Thus, actions are
still required to improve the performance of laboratories and report correct data on
Campylobacter spp. worldwide.
Performance (pass/fail) criteria were not speciﬁed for the Campylobacter species
identiﬁcation module, although the average of 79.3% correctly identiﬁed strains indi-
cates that some laboratories would need to assess their routine to improve their
performance. Assessing the general performance of the AST component of all partici-
pating laboratories over the 4 years, the average deviation level at 7.3% exceeds the
deﬁned acceptance limit of 5%. The development in the annual deviation levels,
however, could not indicate a trend with statistical signiﬁcance. For the AST, the high
level of incorrectly reported results is critical, especially for macrolides (8.5%) and
ﬂuoroquinolones (6.4%), since these two antimicrobial classes are the preferred choice
for treatment.
The frequent incidence of Campylobacter diarrhea, increasing drug resistance, and
the potential for long-term sequelae highlight the importance of accurately under-
standing the socioeconomic burden of campylobacteriosis (1). Increased competence
FIG 5 Antimicrobial susceptibility testing of Campylobacter spp. Summary of the performance per year of results
covering all nine participating regions (Africa, Asia/Middle East, Caribbean, Europe, Latin America, North America,
Oceania, Russia, and Southeast Asia).
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of reference laboratories for identiﬁcation and AST of C. jejuni and C. coli therefore
supports disease surveillance and control programs. However, the ability of a referral
center to impact surveillance is contingent upon an isolate/specimen ﬂow from ﬁrst-
line laboratories. On average, only 50% of EQAS participants reported results for
Campylobacter spp., suggesting widespread gaps in capacity. The advancement in
whole-genome sequencing and in silico bioinformatics tools combined with lower
prices is a promising development in enhancing the ability of national reference
laboratories to correctly identify and perform susceptibility testing of Campylobacter
spp. in the future. Similarly, molecular assays and other culture-independent tests may
increase surveillance capacity at the clinical level. While these technologies currently
are not a substitute for culture, they may provide estimates of burden and help
determine which specimens should be subjected to conventional culture.
The self-evaluation design of this proﬁciency test was intended to challenge the
participating laboratories to assess their current identiﬁcation and AST methods for
Campylobacter spp., while allowing them to include the proﬁciency test outcome as an
external quality assessment of the relevant methods. Self-evaluation is a concept well
known to laboratories following a quality assurance standard requiring quality control
procedures, e.g., ISO/IEC 17025:2005 (9), and might include monitoring the validity of
test results by the regular use of an internal quality control using reference materials or
participation in proﬁciency-testing programs. Apart from the obvious connection to the
WHO GFN EQAS as a proﬁciency test, laboratories participating in the program are
offered material for internal control in the form of both the certiﬁed ATCC reference
strain, C. jejuni ATCC 33560, and the test strains, which can be regarded as internal
control strains and, consequently, should be stored and maintained.
In addition to self-evaluation, the possibility of introducing approaches, such as
mentoring of participants, training courses, and E-learning, could be explored and
suggested to the participants. The question of resources must, however, be considered;
for example, mentoring of participants appears to be a rewarding but also a resource-
demanding approach of capacity building. Regional follow-up is likely to be a reward-
ing approach and should be based on an evaluation of regional needs and challenges.
Especially for the African and Southeast Asia regions, it appears that speciﬁc follow-up
is required. For example, the submitted results for the AST component indicate that
many laboratories did not perform adequate internal quality control (17.2% of submit-
ted results for the ATCC reference strain were out of range), which is why WHO GFN
capacity-building efforts focus on encouraging the maintenance of relevant quality
assurance as part of the laboratory routines. Internal laboratory quality assurance (QA)
ensures the minimization of variable factors inﬂuencing the obtained result for a test
strain. These factors include the medium content, the activity of the antimicrobial, and
the testing of a QC reference strain according to an internationally recognized standard
(e.g., one by the CLSI). Laboratories that have introduced relevant quality assurance of
the variable factors facilitate good performance. For all laboratories performing AST of
Campylobacter species, testing of the C. jejuni reference strain (ATCC 33560) should be
a routine QA measure providing quality control for both the method and the reagents.
Moreover, results outside the quality control ranges should always induce an appro-
priate follow-up.
In conclusion, this annually provided proﬁciency test supports the identiﬁcation and
AST of Campylobacter spp. and allows national reference laboratories, free of charge, to
evaluate their obtained results by comparison to quality-assured and veriﬁed expected
results. Overall, we found that global ability to correctly identify Campylobacter spp.
ﬂuctuated over the years up to 90.7%, and the ability to correctly perform AST
appeared to steadily increase to 93.6%. African laboratories, followed by Southeast
Asian laboratories, had the lowest performance in both identifying the Campylobacter
spp. and conducting AST. Our results reveal a worrisome tendency where approxi-
mately 10% of laboratories reported either an incorrect diagnosis or antimicrobial
susceptibility proﬁle for treatment. This issue will compromise the ability to correctly
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diagnose illness and effectively treat patients, and it will provide unreliable data for
pathogen and AST surveillance systems if not addressed.
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